1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Multiplex Assay Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Planar Nucleic Acid Assays
1.2.3 Bead-Based Nucleic Acid Assays
1.2.4 Other Nucleic Acid Assays
1.3 Market by Application
1.3.1 Global Nucleic Acid Multiplex Assay Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical & Biotechnology Companies
1.3.3 Hospitals & Research Institutes
1.3.4 Reference Laboratories
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Multiplex Assay Market Perspective (2018-2029)
2.2 Nucleic Acid Multiplex Assay Growth Trends by Region
2.2.1 Global Nucleic Acid Multiplex Assay Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nucleic Acid Multiplex Assay Historic Market Size by Region (2018-2023)
2.2.3 Nucleic Acid Multiplex Assay Forecasted Market Size by Region (2024-2029)
2.3 Nucleic Acid Multiplex Assay Market Dynamics
2.3.1 Nucleic Acid Multiplex Assay Industry Trends
2.3.2 Nucleic Acid Multiplex Assay Market Drivers
2.3.3 Nucleic Acid Multiplex Assay Market Challenges
2.3.4 Nucleic Acid Multiplex Assay Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid Multiplex Assay Players by Revenue
3.1.1 Global Top Nucleic Acid Multiplex Assay Players by Revenue (2018-2023)
3.1.2 Global Nucleic Acid Multiplex Assay Revenue Market Share by Players (2018-2023)
3.2 Global Nucleic Acid Multiplex Assay Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid Multiplex Assay Revenue
3.4 Global Nucleic Acid Multiplex Assay Market Concentration Ratio
3.4.1 Global Nucleic Acid Multiplex Assay Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Multiplex Assay Revenue in 2022
3.5 Nucleic Acid Multiplex Assay Key Players Head office and Area Served
3.6 Key Players Nucleic Acid Multiplex Assay Product Solution and Service
3.7 Date of Enter into Nucleic Acid Multiplex Assay Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Multiplex Assay Breakdown Data by Type
4.1 Global Nucleic Acid Multiplex Assay Historic Market Size by Type (2018-2023)
4.2 Global Nucleic Acid Multiplex Assay Forecasted Market Size by Type (2024-2029)
5 Nucleic Acid Multiplex Assay Breakdown Data by Application
5.1 Global Nucleic Acid Multiplex Assay Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid Multiplex Assay Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nucleic Acid Multiplex Assay Market Size (2018-2029)
6.2 North America Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
6.4 North America Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid Multiplex Assay Market Size (2018-2029)
7.2 Europe Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
7.4 Europe Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid Multiplex Assay Market Size (2018-2029)
8.2 Asia-Pacific Nucleic Acid Multiplex Assay Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nucleic Acid Multiplex Assay Market Size by Region (2018-2023)
8.4 Asia-Pacific Nucleic Acid Multiplex Assay Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid Multiplex Assay Market Size (2018-2029)
9.2 Latin America Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
9.4 Latin America Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid Multiplex Assay Market Size (2018-2029)
10.2 Middle East & Africa Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
10.4 Middle East & Africa Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Luminex Corporation (US)
11.1.1 Luminex Corporation (US) Company Detail
11.1.2 Luminex Corporation (US) Business Overview
11.1.3 Luminex Corporation (US) Nucleic Acid Multiplex Assay Introduction
11.1.4 Luminex Corporation (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.1.5 Luminex Corporation (US) Recent Development
11.2 Thermo Fisher Scientific Inc. (US)
11.2.1 Thermo Fisher Scientific Inc. (US) Company Detail
11.2.2 Thermo Fisher Scientific Inc. (US) Business Overview
11.2.3 Thermo Fisher Scientific Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.2.4 Thermo Fisher Scientific Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.2.5 Thermo Fisher Scientific Inc. (US) Recent Development
11.3 Illumina, Inc (US)
11.3.1 Illumina, Inc (US) Company Detail
11.3.2 Illumina, Inc (US) Business Overview
11.3.3 Illumina, Inc (US) Nucleic Acid Multiplex Assay Introduction
11.3.4 Illumina, Inc (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.3.5 Illumina, Inc (US) Recent Development
11.4 Bio-Rad Laboratories, Inc. (US)
11.4.1 Bio-Rad Laboratories, Inc. (US) Company Detail
11.4.2 Bio-Rad Laboratories, Inc. (US) Business Overview
11.4.3 Bio-Rad Laboratories, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.4.4 Bio-Rad Laboratories, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.4.5 Bio-Rad Laboratories, Inc. (US) Recent Development
11.5 Qiagen N.V. (Netherlands)
11.5.1 Qiagen N.V. (Netherlands) Company Detail
11.5.2 Qiagen N.V. (Netherlands) Business Overview
11.5.3 Qiagen N.V. (Netherlands) Nucleic Acid Multiplex Assay Introduction
11.5.4 Qiagen N.V. (Netherlands) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.5.5 Qiagen N.V. (Netherlands) Recent Development
11.6 Abcam plc (UK)
11.6.1 Abcam plc (UK) Company Detail
11.6.2 Abcam plc (UK) Business Overview
11.6.3 Abcam plc (UK) Nucleic Acid Multiplex Assay Introduction
11.6.4 Abcam plc (UK) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.6.5 Abcam plc (UK) Recent Development
11.7 Becton, Dickinson and Company (US)
11.7.1 Becton, Dickinson and Company (US) Company Detail
11.7.2 Becton, Dickinson and Company (US) Business Overview
11.7.3 Becton, Dickinson and Company (US) Nucleic Acid Multiplex Assay Introduction
11.7.4 Becton, Dickinson and Company (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.7.5 Becton, Dickinson and Company (US) Recent Development
11.8 Merck KGaA (Germany)
11.8.1 Merck KGaA (Germany) Company Detail
11.8.2 Merck KGaA (Germany) Business Overview
11.8.3 Merck KGaA (Germany) Nucleic Acid Multiplex Assay Introduction
11.8.4 Merck KGaA (Germany) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.8.5 Merck KGaA (Germany) Recent Development
11.9 Agilent Technologies, Inc. (US)
11.9.1 Agilent Technologies, Inc. (US) Company Detail
11.9.2 Agilent Technologies, Inc. (US) Business Overview
11.9.3 Agilent Technologies, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.9.4 Agilent Technologies, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.9.5 Agilent Technologies, Inc. (US) Recent Development
11.10 Meso Scale Diagnostics (US)
11.10.1 Meso Scale Diagnostics (US) Company Detail
11.10.2 Meso Scale Diagnostics (US) Business Overview
11.10.3 Meso Scale Diagnostics (US) Nucleic Acid Multiplex Assay Introduction
11.10.4 Meso Scale Diagnostics (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.10.5 Meso Scale Diagnostics (US) Recent Development
11.11 Randox Laboratories (UK)
11.11.1 Randox Laboratories (UK) Company Detail
11.11.2 Randox Laboratories (UK) Business Overview
11.11.3 Randox Laboratories (UK) Nucleic Acid Multiplex Assay Introduction
11.11.4 Randox Laboratories (UK) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.11.5 Randox Laboratories (UK) Recent Development
11.12 Quanterix (US)
11.12.1 Quanterix (US) Company Detail
11.12.2 Quanterix (US) Business Overview
11.12.3 Quanterix (US) Nucleic Acid Multiplex Assay Introduction
11.12.4 Quanterix (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.12.5 Quanterix (US) Recent Development
11.13 Bio-Techne Corporation (US)
11.13.1 Bio-Techne Corporation (US) Company Detail
11.13.2 Bio-Techne Corporation (US) Business Overview
11.13.3 Bio-Techne Corporation (US) Nucleic Acid Multiplex Assay Introduction
11.13.4 Bio-Techne Corporation (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.13.5 Bio-Techne Corporation (US) Recent Development
11.14 Olink (Sweden)
11.14.1 Olink (Sweden) Company Detail
11.14.2 Olink (Sweden) Business Overview
11.14.3 Olink (Sweden) Nucleic Acid Multiplex Assay Introduction
11.14.4 Olink (Sweden) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.14.5 Olink (Sweden) Recent Development
11.15 DiaSorin S.p.A. (Italy)
11.15.1 DiaSorin S.p.A. (Italy) Company Detail
11.15.2 DiaSorin S.p.A. (Italy) Business Overview
11.15.3 DiaSorin S.p.A. (Italy) Nucleic Acid Multiplex Assay Introduction
11.15.4 DiaSorin S.p.A. (Italy) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.15.5 DiaSorin S.p.A. (Italy) Recent Development
11.16 Seegene (South Korea)
11.16.1 Seegene (South Korea) Company Detail
11.16.2 Seegene (South Korea) Business Overview
11.16.3 Seegene (South Korea) Nucleic Acid Multiplex Assay Introduction
11.16.4 Seegene (South Korea) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.16.5 Seegene (South Korea) Recent Development
11.17 Promega Corporation (US)
11.17.1 Promega Corporation (US) Company Detail
11.17.2 Promega Corporation (US) Business Overview
11.17.3 Promega Corporation (US) Nucleic Acid Multiplex Assay Introduction
11.17.4 Promega Corporation (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.17.5 Promega Corporation (US) Recent Development
11.18 Siemens Healthineers (Germany)
11.18.1 Siemens Healthineers (Germany) Company Detail
11.18.2 Siemens Healthineers (Germany) Business Overview
11.18.3 Siemens Healthineers (Germany) Nucleic Acid Multiplex Assay Introduction
11.18.4 Siemens Healthineers (Germany) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.18.5 Siemens Healthineers (Germany) Recent Development
11.19 PerkinElmer, Inc. (US)
11.19.1 PerkinElmer, Inc. (US) Company Detail
11.19.2 PerkinElmer, Inc. (US) Business Overview
11.19.3 PerkinElmer, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.19.4 PerkinElmer, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.19.5 PerkinElmer, Inc. (US) Recent Development
11.20 Shimadzu Biotech (Japan)
11.20.1 Shimadzu Biotech (Japan) Company Detail
11.20.2 Shimadzu Biotech (Japan) Business Overview
11.20.3 Shimadzu Biotech (Japan) Nucleic Acid Multiplex Assay Introduction
11.20.4 Shimadzu Biotech (Japan) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.20.5 Shimadzu Biotech (Japan) Recent Development
11.21 Antigenix America, Inc. (US)
11.21.1 Antigenix America, Inc. (US) Company Detail
11.21.2 Antigenix America, Inc. (US) Business Overview
11.21.3 Antigenix America, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.21.4 Antigenix America, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.21.5 Antigenix America, Inc. (US) Recent Development
11.22 Enzo Life Sciences, Inc. (US)
11.22.1 Enzo Life Sciences, Inc. (US) Company Detail
11.22.2 Enzo Life Sciences, Inc. (US) Business Overview
11.22.3 Enzo Life Sciences, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.22.4 Enzo Life Sciences, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.22.5 Enzo Life Sciences, Inc. (US) Recent Development
11.23 Boster Biological Technology (US)
11.23.1 Boster Biological Technology (US) Company Detail
11.23.2 Boster Biological Technology (US) Business Overview
11.23.3 Boster Biological Technology (US) Nucleic Acid Multiplex Assay Introduction
11.23.4 Boster Biological Technology (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.23.5 Boster Biological Technology (US) Recent Development
11.24 AYOXXA Biosystems GmbH (Germany)
11.24.1 AYOXXA Biosystems GmbH (Germany) Company Detail
11.24.2 AYOXXA Biosystems GmbH (Germany) Business Overview
11.24.3 AYOXXA Biosystems GmbH (Germany) Nucleic Acid Multiplex Assay Introduction
11.24.4 AYOXXA Biosystems GmbH (Germany) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.24.5 AYOXXA Biosystems GmbH (Germany) Recent Development
11.25 Cayman Chemical Company (US)
11.25.1 Cayman Chemical Company (US) Company Detail
11.25.2 Cayman Chemical Company (US) Business Overview
11.25.3 Cayman Chemical Company (US) Nucleic Acid Multiplex Assay Introduction
11.25.4 Cayman Chemical Company (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.25.5 Cayman Chemical Company (US) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
※参考情報 核酸マルチプレックスアッセイは、複数の核酸(DNAまたはRNA)を同時に検出・定量するための技術であり、近年の生命科学研究や診断技術の進展において重要な役割を果たしています。この技術は、特に病原体の検出や遺伝子の解析においてその有効性を発揮します。 核酸マルチプレックスアッセイの定義としては、特定の条件下で複数の核酸配列を一度のアッセイで同時に分析できる手法を指します。これにより、対象とする核酸の数が増加し、効率的かつ迅速な分析が可能になります。特に、複数の病原体や遺伝子変異を一度に検出する必要がある場合に非常に有用です。 このアッセイの特徴としては、いくつかの点が挙げられます。一つは、同時に複数のターゲットを解析できるため、時間の短縮とコストの削減が可能になることです。また、この技術は高感度と高特異性を兼ね備えているため、病原体の検出精度も向上します。さらに、核酸マルチプレックスアッセイは、サンプルの種類や検出対象によって柔軟に設計できるため、用途の幅が広いという利点もあります。 具体的な種類としては、リアルタイムPCR(Polymerase Chain Reaction)、ハイブリダイゼーションベースのアッセイ、次世代シーケンシング(NGS: Next Generation Sequencing)などがあります。リアルタイムPCRは、特定のDNA配列を増幅しながら、増幅の進行をリアルタイムで測定する手法です。この手法では、蛍光標識されたプライマーやプローブを使用することで、特異的な検出が可能になります。 ハイブリダイゼーションベースのアッセイは、特定の配列に対するプローブを用いて、ターゲットとする核酸を検出する方法です。これには、スライドやマイクロアレイを使った手法が含まれます。さまざまなプローブが一つの支持体上に配置され、複数のターゲットを同時に検出できます。 さらに、次世代シーケンシングは、より高いスループットを実現し、膨大な量のデータを提供することができる技術です。この技術を用いることで、全ゲノムの解析や複雑なサンプル中の微量の核酸の同定が行えます。 用途としては、医学分野での病原体の同時検出、遺伝子変異解析、がんのバイオマーカーの同定、さらには食品安全検査や環境モニタリングにまで及びます。特に感染症の診断においては、複数の病原体を一度に検出できるため、迅速な治療方針の決定に寄与します。 また、研究の現場では、複合的な遺伝子発現解析や、疾患のメカニズム解明に役立つデータを得ることができます。これにより、個別化医療やバイオマーカーの同定に向けた研究が進展しています。 関連する技術として、バイオインフォマティクスが挙げられます。データ量が膨大になる次世代シーケンシングの結果を解析するためには、高度なアルゴリズムやデータ分析手法が必要です。これにより、得られたデータの有意義な解釈や、ターゲットの同定が可能になります。 まとめとして、核酸マルチプレックスアッセイは、検出精度の向上や効率的なサンプル解析を実現するための重要な技術です。今後も、この技術はさらなる進化を遂げ、医療や研究の現場での利用が拡大することが期待されています。また、新たな技術革新や応用が進むことで、より多くの分野での活用が見込まれています。これにより、生命科学の発展に寄与することが期待されており、我々の理解を深め、より良い医療を提供するための一助となるでしょう。 |